MTND2P11

Across TCGA pan-cancer cohorts, MTND2P11 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated MTND2P11 data layer.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher MTND2P11 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTND2P11 expression acts as an unfavorable survival marker, although some lineages such as MESO and BLCA show a favorable association.

COAD, MESO, and BLCA are the cancer types where MTND2P11 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Tertile	IV	0.045	0.659	<.001	81	view →
MESO	OS	Tertile	All	1.000	0.258	.025	24	view →
BLCA	DFS	Tertile	IV	0.455	0.181	.020	18	view →
LUAD	DFS	Tertile	IV	0.632	0.929	.035	18	view →
UCEC	OS	Tertile	IV	0.209	0.530	.037	18	view →
LIHC	OS	Tertile	All	0.452	0.717	.048	9	view →
ESCA	OS	Median	II,III,IV	0.617	1.000	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MTND2P11–COAD (OS)

Open the COAD breakdown →